Designing protein binders for drug development, diagnostics and research
Protein binders must do more than attach to a target: they need specificity, function and properties suitable for development. Optimising stability, production and binding can involve a long, expensive cycle. Laboratory testing must keep pace as computational design produces candidates faster.
AffinityAI designs custom protein binders with AI and tests them in the laboratory. Partners specify a target, and the company develops candidates tailored for specificity, stability and function for drug development, diagnostics and research.
What stands out about AffinityAI
Partnered with LenioBio to combine AI protein design with ALiCE cell-free expression for faster testing and optimisation.
Selected for BioInnovation Institute's fall 2026 cohort, with programme support for scientific, business and team development.
Co-founder Timothy Jenkins is a DTU associate professor and heads its Center for Translational Protein Design.
Accepted into AI Launchpad, a pan-European startup growth programme supported by Rise Europe and the ELIAS initiative.
BioInnovation Institute identifies AffinityAI as a spinout from the Technical University of Denmark in its fall 2026 cohort.
Collaborates with NeoTargets to combine AI target discovery and biological validation with de novo protein design for oncology.
Reports receiving Innovation Fund Denmark funding to expand the scope, complexity and performance of its protein design platform.
Co-founder Esperanza Rivera de Torre is a DTU associate professor researching antigen engineering and immune-response modulation.
Reports in vitro binding validation against a flexible, disordered peptide target in a contracted protein-design campaign.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.